Phase I/II study of peptide pulsed dendritic cell vaccination combined with carboplatin and paclitaxel for patients with advanced malignant melanoma
- Conditions
- unresectable malignant melanoma
- Registration Number
- JPRN-UMIN000006629
- Lead Sponsor
- Keio University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1)Patients who have active other primary malignancies 2)Patients who have past history of severe allergy 3)Patients who have severe comorbidity (infections, interstitial pneumonia, fibroid lung, cardiovascular disease, renal disease, liver disease, uncontrolled diabetes) 4)Patients who have pleural effusion or pericardial fluid requiring treatment 5)Patients who are pregnant or nursing 6)Male hope to impregnate 7)Carrier of HBV, HCV, HTLV-1, HIV and so on 8)Patients who have severe psychiatric disease 9)Patients who have past history of autoimmune disease 10)During treatment with immunosuppressive agents 11)During treatment with Disulfiram, Cyanamide, carmofur or Procarbazine Hydrochloride 12)Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events Response rate Progression free survival Overall survival
- Secondary Outcome Measures
Name Time Method Immune induction (Delayed type hypersensitivity DTH for melanoma-antigen peptide)